Pay in 4 interest-free payments of $5.14 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
While it's too early to know exactly how GLP-1 drugs' will ripple out to the broader economy long-term, it's already had significant effects on patients' consumption, and companies are keeping an eye out for future developments
Private access surged from zero to 43.8% of total estimated use by April 2025. Media enquiries For enquiries about this story and interview requests please contact Michelle Smith: Phone: +61 410 116 257 Email: [email protected] How researchers quantified population-level trends in GLP-1 medicine use for the first time Data on subsidised access to GLP-1 medicines has been widely available in many countries, however, there has been a gap in information on private, non-subsidised use, making it harder for policymakers to make decisions on expanding access via Australias Pharmaceutical Benefits Scheme, said A/Prof
Microbiome uncertainty: While bacterial shifts may be helpful, the long-term effects arent fully known and may contribute to bloating or unpredictable bowel habits
As their use expands globally, it becomes increasingly important to evaluate all components of these therapies, not just the active compound." Story Source: Materials provided by Adelaide University
Take Medications with Food : For some individuals, taking medications with food can reduce the chances of experiencing digestive upset
